June 2016, Vol 7, No 5

The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (Tagrisso) targetsEGFR mutations, including T790M. Osimertinib was approved by the FDA in November 2015 for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and theT790M mutation whose disease progressed during or after EGFR TKI therapy.